Circulating MicroRNAs as Non-invasive Biomarkers for Canine Cushing's Syndrome

Sanders, Karin; Veldhuizen, Anouk; Kooistra, Hans S.; Slob, Adri; Timmermans-Sprang, Elpetra P. M.; Riemers, Frank M.; Daminet, Sylvie; Fracassi, Federico; Nimwegen, S.A. van; Meij, Björn P.; Galac, Sara

doi:10.3389/fvets.2021.760487

Cited by 6 publications

(5 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The majority of studies used only a single method of evaluation including reverse transcription-quantitative polymerase chain reaction (RT-qPCR) ( 8 , 10–13 , 16 , 17 , 19 , 27 , 31 , 33 , 36 , 37 , 40–43 , 47 , 49 , 50 , 52 , 54 , 55 , 59 , 60 , 62 , 68–121 , 25 –), microarray ( 44 , 53 , 122–125 ), or next generation sequencing (NGS) ( 32 , 38 , 126–131 ), Some studies evaluated the miRNA through two methods including NGS with validation via RT-qPCR ( 29 , 30 , 35 , 39 , 40 , 45 , 46 , 51 , 56 , 61 , 63 , 65 , 67 , 132–144 ),microarray with validation via RT-qPCR ( 5 , 9 , 14 , 18 , 28 , 57 , 58 , 64 , 66 , 145–149 ), one study utilized NGS with validation using digital drop PCR (ddPCR) ( 7 ), one study utilized nanostring with qRT-PCR ( 20 ), and two studies utilized in situ hybridization (ISH) for validation of their findings ( 39 , 109 ).…”

Section: Resultsmentioning

confidence: 99%

A review on microRNA detection and expression studies in dogs

Varvil,

dos Santos

2023

Front. Vet. Sci.

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are small non-coding RNAs that function by post-transcriptional regulation of gene expression. Their stability and abundance in tissue and body fluids makes them promising potential tools for both the diagnosis and prognosis of diseases and attractive therapeutic targets in humans and dogs. Studies of miRNA expression in normal and disease processes in dogs are scarce compared to studies published on miRNA expression in human disease. In this literature review, we identified 461 peer-reviewed papers from database searches using the terms “canine,” “dog,” “miRNA,” and “microRNA”; we screened 244 for inclusion criteria and then included a total of 148 original research peer-reviewed publications relating to specific miRNA expression in canine samples. We found an overlap of miRNA expression changes between the four groups evaluated (normal processes, non-infectious and non-inflammatory conditions, infectious and/or inflammatory conditions, and neoplasia) in 39 miRNAs, 83 miRNAs in three of the four groups, 110 miRNAs in two of the three groups, where 158 miRNAs have only been reported in one of the groups. Additionally, the mechanism of action of these overlapping miRNAs varies depending on the disease process, elucidating a need for characterization of the mechanism of action of each miRNA in each disease process being evaluated. Herein we also draw attention to the lack of standardization of miRNA evaluation, consistency within a single evaluation method, and the need for standardized methods for a direct comparison.

show abstract

Section: Resultsmentioning

confidence: 99%

A review on microRNA detection and expression studies in dogs

Varvil,

dos Santos

2023

Front. Vet. Sci.

View full text Add to dashboard Cite

show abstract

“…In contrast, the expression of serum miR‐375 was detected in all dogs with AP and in healthy dogs in this study. In this study, cel‐miR‐39‐3p was chosen as spike‐in control as it has been used in many studies regarding the expression of serum miRNAs in dogs; additionally, the primer for cel‐miR‐39‐3p is commercially available 28‐30 …”

Section: Discussionmentioning

confidence: 99%

“…In this study, cel‐miR‐39‐3p was chosen as spike‐in control as it has been used in many studies regarding the expression of serum miRNAs in dogs; additionally, the primer for cel‐miR‐39‐3p is commercially available. 28 , 29 , 30 …”

Section: Discussionmentioning

confidence: 99%

“…In this study, cel-miR-39-3p was chosen as spike-in control as it has been used in many studies regarding the expression of serum miRNAs in dogs; additionally, the primer for cel-miR-39-3p is commercially available. [28][29][30] MiR-375 is highly expressed in the pancreatic islets of Langerhans and regulates beta cell function. 16,31,32 The results of our study are in line with those of a previous report on upregulated serum miR-375 compared with controls in murine and canine models of AP.…”

Section: Comparison Of Pre-and Post-treatment Serum Mirna Expression ...mentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of serummiR‐216a andmiR‐375 as biomarkers in dogs with acute pancreatitis

Lee

Yun

Koo

et al. 2022

Veterinary Internal Medicne

View full text Add to dashboard Cite

Background Serum microRNAs have emerged as biomarkers of various diseases. Overexpression of serum miR‐216a and miR‐375 occurs in dogs with experimentally induced acute pancreatitis (AP). Objectives To identify the possibility of using serum miR‐216a and miR‐375 as biomarkers for the diagnosis and evaluation of treatment response in dogs with naturally occurring AP. Animals Twenty‐one dogs with AP and 20 healthy dogs. Methods Cross‐sectional study. The relative expression of serum hsa‐miR‐216a‐5p, cfa‐miR‐216a, and cfa‐miR‐375 were analyzed using reverse transcription and real‐time PCR. Results A significant difference in the serum expression of cfa‐miR‐375 was found between dogs with AP (median [interquartile range] 3.59 [1.55‐24.52]‐fold) and healthy dogs (0.81 [0.54‐2.21]‐fold, P < .001), and no significant differences were observed in hsa‐miR‐216a‐5p and cfa‐miR‐216a (P > .05). The area under the receiver operating characteristic curve of serum cfa‐miR‐375 for differentiating between AP dogs and healthy dogs was 0.84 (95% confidence interval [CI]: 0.71‐0.96). The expressions of hsa‐miR‐216a‐5p and cfa‐miR‐375 were positively correlated with the concentrations of serum C‐reactive protein (rs = .46, rs = .48, respectively), but not with the serum specific canine pancreatic lipase. The expression of cfa‐miR‐375 was significantly less after treatment in dogs with AP (P = .02). Conclusions and Clinical Importance Serum cfa‐miR‐375 could be a potential biomarker for the diagnosis and evaluation of treatment response of AP in dogs. In addition, miR‐216a and miR‐375 could be associated with inflammatory processes in dogs with AP.

show abstract

“…Circulating miRNAs are small, single-stranded noncoding RNAs in a variety of body fluids that regulate numerous immunologic and inflammatory pathways by inhibiting mRNA translation or promoting mRNA degradation [ 2 , 3 ]. SLE patients have unique miRNA signatures in peripheral blood cells, plasma, and body fluids.…”

Section: Introductionmentioning

confidence: 99%

Circulating miR-320b Contributes to CD4+ T-Cell Proliferation in Systemic Lupus Erythematosus via MAP3K1

Li,

Wang,

Wang

et al. 2023

Journal of Immunology Research

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by the production of autoantibodies and tissue inflammation. Mesenchymal stem cells (MSCs) have emerged as a promising candidate therapy for SLE owing to the immunomodulatory and regenerative properties. Circulating miRNAs are small, single-stranded noncoding RNAs in a variety of body fluids that regulate numerous immunologic and inflammatory pathways. Recent studies have revealed many differentially expressed circulating miRNAs in autoimmune diseases including SLE. However, the role of circulating miRNAs in SLE has not been extensively studied. Here, we performed small RNA sequencing analysis to compare the circulating miRNA profiles of SLE patients before and after MSC transplantation (MSCT), and identified a significant decrease of circulating miR-320b level during MSCT. Importantly, we found that the expression of circulating miR-320b and its target gene MAP3K1 was closely associated with SLE disease activity. The in vitro experiments showed that decreased MAP3K1 level in SLE peripheral blood mononuclear cells (PBMCs) was involved in CD4+ T-cell proliferation. In MRL/lpr mice, miR-320b overexpression aggravated symptoms of SLE, while miR-320b inhibition could promote disease remission. Besides, MSCs regulate miR-320b/MAP3K1 expression both in vitro and in vivo. Our results suggested that circulating miR-320b and MAP3K1 may be involved in CD4+ T-cell proliferation in SLE. This trial is registered with NCT01741857.

show abstract

Circulating MicroRNAs as Non-invasive Biomarkers for Canine Cushing's Syndrome

Cited by 6 publications

References 54 publications

A review on microRNA detection and expression studies in dogs

A review on microRNA detection and expression studies in dogs

Evaluation of serummiR‐216a andmiR‐375 as biomarkers in dogs with acute pancreatitis

Circulating miR-320b Contributes to CD4+ T-Cell Proliferation in Systemic Lupus Erythematosus via MAP3K1

Contact Info

Product

Resources

About